{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:49Z","timestamp":1792123789046,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11899-023-00696-6","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:01:27Z","timestamp":1684299687000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-3539","authenticated-orcid":false,"given":"Guadalupe","family":"Ferreira Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"696_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3904\/kjim.2018.033","volume":"33","author":"K Takenaka","year":"2018","unstructured":"Takenaka K, Shimoda K, Akashi K. Recent advances in the diagnosis and management of primary myelofibrosis. Korean Journal of Internal Medicine. Korean Assoc Int Med. 2018;33:679\u201390.","journal-title":"Korean Assoc Int Med"},{"issue":"5","key":"696_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s12185-022-03299-8","volume":"115","author":"D Tremblay","year":"2022","unstructured":"\u2022 Tremblay D, Mesa R. Novel treatments for myelofibrosis: beyond JAK inhibitors. Int J Hematol. 2022;115(5):645\u201358. https:\/\/doi.org\/10.1007\/s12185-022-03299-8. Review of the current growing treatment landscape in MF.","journal-title":"Int J Hematol"},{"issue":"1","key":"696_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145\u201362.","journal-title":"Am J Hematol"},{"issue":"27","key":"696_CR4","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2217\/fon-2022-0484","volume":"18","author":"CN Harrison","year":"2022","unstructured":"\u2022\u2022 Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, et al. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022;18(27):2987\u201397. First Phase III study assessing combination therapy as first-line treatment for patients with MF without prior JAKi exposure.","journal-title":"Future Oncol"},{"key":"696_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/17474086.2017.1317590","volume":"10","author":"M Stahl","year":"2017","unstructured":"Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Rev Hematol. 2017;10:459\u201377.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"696_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348\u201355.","journal-title":"Am J Hematol"},{"key":"696_CR7","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/cncr.34222","volume":"128","author":"JO Mascarenhas","year":"2022","unstructured":"Mascarenhas JO, Verstovsek S. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer. 2022;128:2717\u201327.","journal-title":"Cancer"},{"key":"696_CR8","doi-asserted-by":"crossref","unstructured":"Harrison C, Kiladjian JJ, Kathrin Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V, et al. N Engl J Med 2012;366(9):787-798","DOI":"10.1056\/NEJMoa1110556"},{"issue":"7","key":"696_CR9","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317-24.","journal-title":"Lancet Haematol"},{"issue":"5","key":"696_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol. 2018;4(5):652\u20139.","journal-title":"JAMA Oncol"},{"issue":"8","key":"696_CR11","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia. 2019;33(8):1978\u201395.","journal-title":"Leukemia"},{"issue":"6","key":"696_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243\u201352.","journal-title":"Cancer"},{"issue":"3","key":"696_CR13","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.4155\/fsoa-2018-0115","volume":"5","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T, et al. Bromodomain and extra-terminal motif inhibitors: A review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):2056\u20135623. https:\/\/doi.org\/10.4155\/fsoa-2018-0115.","journal-title":"Future Sci OA"},{"issue":"1","key":"696_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"\u2022 Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018;33(1):29\u201343. Preclinical evidence of synergistic activity of combination therapy with BET-inhibitor and JAKi for treatment of MF.","journal-title":"Cancer Cell"},{"issue":"7327","key":"696_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119\u201323.","journal-title":"Nature"},{"key":"696_CR16","doi-asserted-by":"publisher","unstructured":"Stathis A, Bertoni F. BET Proteins as Targets for Anticancer Treatment. Cancer Discovery 2018;24\u201336. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0605.","DOI":"10.1158\/2159-8290.CD-17-0605"},{"key":"696_CR17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","volume":"59","author":"BK Albrecht","year":"2016","unstructured":"Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Co A, Leblanc Y, et al. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. J Med Chem. 2016;59:1330\u20139.","journal-title":"J Med Chem"},{"issue":"5","key":"696_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.beem.2010.09.001","volume":"24","author":"E Peschke","year":"2010","unstructured":"Peschke E, M\u00fchlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab. 2010;24(5):829\u201341.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"696_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4239\/wjd.v2.i6.82","volume":"15","author":"J Espino","year":"2011","unstructured":"Espino J, Pariente J, Rodr\u00edguez A. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes. 2011;15(2):82\u201391.","journal-title":"World J Diabetes"},{"issue":"31","key":"696_CR20","doi-asserted-by":"publisher","first-page":"11365","DOI":"10.1073\/pnas.1411701111","volume":"111","author":"M Ceribelli","year":"2014","unstructured":"Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, et al. Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA. 2014;111(31):11365\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Sup. 1","key":"696_CR21","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1182\/blood-2018-99-119157","volume":"132","author":"M Kremyanskaya","year":"2018","unstructured":"Kremyanskaya M, Hoffman R, Mascarenhas J, Verstovsek S, Mertz J, Garner F, et al. A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF). Blood. 2018;132(Sup. 1):5481\u20135481. https:\/\/doi.org\/10.1182\/blood-2018-99-119157.","journal-title":"Blood"},{"issue":"51","key":"696_CR22","doi-asserted-by":"publisher","first-page":"15713","DOI":"10.1073\/pnas.1522163112","volume":"112","author":"N Ding","year":"2015","unstructured":"Ding N, Hah N, Yu RT, Sherman MH, Benner C, Leblanc M, et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci USA. 2015;112(51):15713\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"696_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","volume":"2","author":"KA Blum","year":"2022","unstructured":"Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, et al. A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer Res Commun. 2022;2(8):795\u2013805.","journal-title":"Cancer Res Commun"},{"issue":"Sup.1","key":"696_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2021-150172","volume":"138","author":"M Kremyanskaya","year":"2021","unstructured":"\u2022 Kremyanskaya M, Mascarenhas J, Palandri F, Vannucchi A, Verstovsek S, Harrison CN, et al. Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial. Blood. 2021;138(Sup.1):141. https:\/\/doi.org\/10.1182\/blood-2021-150172. Report of the results of arm 1 (pelabresib monotherapy in JAKi intolerant\/refractory patients) of the Manifest Trial.","journal-title":"Blood"},{"issue":"Sup.2","key":"696_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S2152-2650(22)01456-2","volume":"22","author":"J Mascarenhas","year":"2022","unstructured":"\u2022\u2022 Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, et al. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Na\u00efve or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk. 2022;22(Sup.2):335\u20136. Potentially practice changing data from MANIFEST trial in MF patients with suboptimal response to JAKi (arm 2) and JAKi-na\u00efve (arm 3) treated with combination treatment of pelabresib and ruxolitinib.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Sup.1","key":"696_CR26","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1182\/blood-2022-157735","volume":"140","author":"C Harrison","year":"2022","unstructured":"\u2022 Harrison C, Kremyanskaya M, Bose P, Gupta V, Rampal RK, Lambert J, et al. Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study. Blood. 2022;140(Sup.1):9659\u201362. https:\/\/doi.org\/10.1182\/blood-2022-157735. Updated report of MANIFEST study arm 2 results of pelabresib as add-on to ruxolitinib.","journal-title":"Blood"},{"key":"696_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, et al. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis. J Clin Oncol. 2023;1\u201313. Updated report of MANIFEST study arm 3 results confirming clinical efficacy and disease biomarker findings of combination treatment with pelabresib and ruxolitinib.","DOI":"10.1200\/JCO.22.01972"},{"issue":"9","key":"696_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"Sup.2","key":"696_CR29","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1016\/S2152-2650(22)01448-3","volume":"22","author":"O Zavidij","year":"2022","unstructured":"\u2022\u2022 Zavidij O, Haradhvala NJ, Meyer R, Cui J, Verstovsek S, Oh S, et al. MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood. Clin Lymphoma Myeloma Leuk. 2022;22(Sup.2):S331-2. Report of pelabresib positive effects on potential disease biomarkers in MF patients.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00696-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00696-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00696-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:09:00Z","timestamp":1688515740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00696-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00696-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"23 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C. N. Harrison reports medical writing and grants and contracts from Celgene (BMS), Constellation and Novartis, consulting fees from Keros, Galecto, AOP and Roche, fees for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Celgene, CTI Biopharma, AbbVie, Janssen and Constellation, support fees from Novartis for attending meetings and\/or travel. C. N. Harrison also reports fees for participation on data safety monitoring board or advisory board from Galecto, CTI Biopharma, Roche, Geron, Promedior, AbbVie, AOP Pharma, Sierra Oncology and reports leadership or fiduciary role in other board society, committee or advocacy group for EHA and MPN voice.G.F. Gomes reports no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}